Combination of a phosphatidylinositol3-kinase (PI3K) inhibitor and a mTOR inhibitor

Details for Australian Patent Application No. 2009309616 (hide)

Owner Novartis AG

Inventors Garcia-Echeverria, Carlos; Maira, Sauveur-Michel

Agent Davies Collison Cave

Pub. Number AU-A-2009309616

PCT Pub. Number WO2010/049481

Priority 08168044.9 31.10.08 EP

Filing date 29 October 2009

Wipo publication date 6 May 2010

International Classifications

A61K 31/5377 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

31 March 2011 PCT application entered the National Phase

  PCT publication WO2010/049481 Priority application(s): WO2010/049481

7 July 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 11 May 2011

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009309623-Treating diabetes melitus using insulin injections with less than daily injection frequency

2009309587-Chain for articles conveyor